RecruitingPhase 3NCT07007312
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Studying Acute myeloid leukemia with 11q23 abnormalities
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Kura Oncology, Inc.
- Intervention
- Ziftomenib(drug)
- Enrollment
- 1300 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2031
Study locations (29)
- Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
- University of California, San Diego, La Jolla, California, United States
- Cedars-Sinai Medical Center, Los Angeles, California, United States
- University of California, Irvine, Orange, California, United States
- Colorado Blood Cancer Institute, Denver, Colorado, United States
- Yale University School of Medicine, New Haven, Connecticut, United States
- University of Miami, Miami, Florida, United States
- Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
- University of Kentucky, Lexington, Kentucky, United States
- Wayne State University School of Medicine, Detroit, Michigan, United States
- University of Minnesota, Minneapolis, Minnesota, United States
- Rutgers Biomedical and Health Sciences, New Brunswick, New Jersey, United States
- University of New Mexico, Albuquerque, New Mexico, United States
- Icahn School of Medicine at Mount Sinai, New York, New York, United States
- University of North Carolina, Chapel Hill, Chapel Hill, North Carolina, United States
- +14 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07007312 on ClinicalTrials.govOther trials for Acute myeloid leukemia with 11q23 abnormalities
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06710418Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functional Outcomes in Patients With High-grade Myeloid Neoplasms, Acute Myeloid Leukemia, or B Acute Lymphoblastic Lymphoma/LeukemiaUniversity of Washington
- RECRUITINGPHASE1, PHASE2NCT06928662Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of RelapseFred Hutchinson Cancer Center
- RECRUITINGPHASE1NCT07106749CD180 CART for Relapsed or Refractory CD180 Positive Hematologic MalignanciesInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE1NCT06448013A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid LeukemiaM.D. Anderson Cancer Center
- RECRUITINGPHASE1NCT06245746UCMSC-Exo for Chemotherapy-induced Myelosuppression in Acute Myeloid LeukemiaUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
- RECRUITINGNCT06452732Using Multiparametric Flow Cytometry to Detect Peripheral Blood and Bone Marrow Leukaemia Stem Cells for Relapse Prediction in P-AMLPeking University People's Hospital
- RECRUITINGNCT06458257The Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation in Newly Diagnosed High-relapse-risk CEBPA Mutant Acute Myeloid LeukemiaRuijin Hospital
- RECRUITINGNCT06458244The Efficacy of Allo-HSCT in ND HR-CBF-AMLRuijin Hospital
See all trials for Acute myeloid leukemia with 11q23 abnormalities →